Welcome to Multibagg AI
Log in to access personalized features
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Bearish
3
Neutral
8
Bullish
3
Bearish
34
Neutral
8
Bullish
4
Bearish
31
Neutral
0
Bullish
1
Discovery themes featuring this stock
Metropolis Healthcare Limited is a pan-India clinical diagnostics company operating a large hub-and-spoke laboratory network, offering routine to super-specialty tests, genomics, B2C and B2B services, preventive wellness (TruHealth) and institutional clinical research support across India and selected international markets.
Q3 FY26 organic revenue grew 15% to INR 371 crore with EBITDA of INR 93 crore and margin expansion to 25%, while Group revenue grew 26% to INR 406 crore; PAT excluding exceptional items rose meaningfully, reflecting improving mix, productivity initiatives and economies of scale.
Metropolis is actively premiumising revenue via TruHealth and specialty testing: TruHealth grew ~25% and now contributes 19% of organic revenue, while specialty contribution rose to ~38% driven by genomics, NGS test additions, clinician engagement and AI-enabled interpretation.
Network scale and disciplined M&A are central: the company operates 219 labs and ~4,862 centres, added ~112 centres in Q3, completed four acquisitions (including Core Diagnostics) and launched a Centre of Genomics with Illumina partnership to capture higher-value testing demand.
Financially conservative posture: Metropolis remains net debt-free with cash ~INR 127 crore, FY26 capex guidance of INR 55–60 crore focused on labs, IT and advanced equipment, and the Board approved a 3:1 bonus share proposal signalling confidence in liquidity and shareholder alignment.
Healthcare Services
Healthcare Service Provider
9,350 Cr
Low Risk
55.9
53.4
2.5
6.5
2,259.30
1,383.70
Sales CAGR
Profit CAGR
ROE
ROCE
Metropolis Healthcare Ltd (METROPOLIS) is currently trading at 1,809.95 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Metropolis Healthcare Limited is a pan-India clinical diagnostics company operating a large hub-and-spoke laboratory network, offering routine to super-specialty tests, genomics, B2C and B2B services, preventive wellness (TruHealth) and institutional clinical research support across India and selected international markets. Q3 FY26 organic revenue grew 15% to INR 371 crore with EBITDA of INR 93 crore and margin expansion to 25%, while Group revenue grew 26% to INR 406 crore; PAT excluding exceptional items rose meaningfully, reflecting improving mix, productivity initiatives and economies of scale. Metropolis is actively premiumising revenue via TruHealth and specialty testing: TruHealth grew ~25% and now contributes 19% of organic revenue, while specialty contribution rose to ~38% driven by genomics, NGS test additions, clinician engagement and AI-enabled interpretation. Network scale and disciplined M&A are central: the company operates 219 labs and ~4,862 centres, added ~112 centres in Q3, completed four acquisitions (including Core Diagnostics) and launched a Centre of Genomics with Illumina partnership to capture higher-value testing demand. Financially conservative posture: Metropolis remains net debt-free with cash ~INR 127 crore, FY26 capex guidance of INR 55–60 crore focused on labs, IT and advanced equipment, and the Board approved a 3:1 bonus share proposal signalling confidence in liquidity and shareholder alignment.
Over the past 52 weeks, Metropolis Healthcare Ltd has traded between a low of ₹1,383.70 and a high of ₹2,259.30. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Metropolis Healthcare Ltd has a market capitalization of approximately 9,350.48. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Metropolis Healthcare Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 55.89 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 9,350.48 Cr, Metropolis Healthcare Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Metropolis Healthcare Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Metropolis Healthcare Ltd is 55.89. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Metropolis Healthcare has announced a bonus share issue in the ratio of 3:1, meaning shareholders will receive three new equity shares for every one share they hold.
Metropolis Healthcare reported a 26% year-on-year growth in consolidated revenue for the third quarter of fiscal year 2026.
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Discovery themes featuring this stock
Bonus Issue
Metropolis Healthcare fixed Record Date as Mar 20, 2026 for issuing bonus equity shares in the ratio 3:1 (three new equity shares for every one), with deemed allotment on Mar 23, 2026; resolution passed Mar 10, 2026.
Bonus Issue
Metropolis Healthcare Ltd. announced a 3:1 bonus issue (3 new shares for every 1 existing), record date set for Mar 20, 2026 and deemed allotment on Mar 23, 2026 (ISIN: INE112L01020).
Postal Ballot Outcome
Scrutinizer's report dated 09 Mar 2026: shareholders approved the issue of bonus shares by postal ballot; e-voting (07 Feb–08 Mar 2026) saw 46,954,514 votes (98.36%) in favour, 784,503 (1.64%) against; resolution passed.
Postal Ballot - Bonus Issue
Shareholders approved an ordinary resolution for issue of bonus shares by postal ballot (e‑voting); 46,954,514 votes (98.36%) in favour, 784,503 (1.64%) against; resolution passed (Scrutinizer's Report dated 09-Mar-2026).
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
934.30 | 9,566 Cr | 60.26 | 11.06 | 0.21 | 17.53 | 18.98 | 11.50 | |
1809.95 | 9,350 Cr | 55.89 | 6.53 | 0.00 | 11.05 | 14.12 | 8.50 | |
355.00 | 5,646 Cr | 41.06 | 10.57 | 1.97 | 23.91 | 34.14 | 19.95 | |
538.00 | 5,375 Cr | 67.17 | 4.95 | 0.00 | 8.26 | 14.94 | 0.00 | |
607.55 | 1,971 Cr | 24.89 | 2.14 | 0.45 | 9.16 | 11.09 | 5.34 | |
259.00 | 1,349 Cr | 40.53 | 5.85 | 0.00 | 13.86 | 14.74 | 8.53 | |
591.50 | 1,156 Cr | 23.58 | 11.41 | 0.00 | 43.51 | 58.07 | 27.58 | |
| Median: 7 Co. | 591.50 | 5,375 Cr | 41.06 | 6.53 | 0.00 | 13.86 | 14.94 | 8.53 |
